Pulmonary arterial hypertension targeted for new treatment by University of ºù«Ӱҵ scientists
Scientists at the University of ºù«Ӱҵ, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).